MA26836A1 - Heterocycles azotes bicycliques alkylamino substitues en tant qu'inhibiteurs de kinase de proteine p38. - Google Patents

Heterocycles azotes bicycliques alkylamino substitues en tant qu'inhibiteurs de kinase de proteine p38.

Info

Publication number
MA26836A1
MA26836A1 MA26611A MA26611A MA26836A1 MA 26836 A1 MA26836 A1 MA 26836A1 MA 26611 A MA26611 A MA 26611A MA 26611 A MA26611 A MA 26611A MA 26836 A1 MA26836 A1 MA 26836A1
Authority
MA
Morocco
Prior art keywords
protein kinase
kinase inhibitors
substituted bicyclic
nitrogen heterocycles
alkylamino substituted
Prior art date
Application number
MA26611A
Other languages
English (en)
Inventor
James Patrick Dunn
David Michael Goldstein
Ian Edward David Smith
William Harris
Teresa Rosanne Welch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26836A1 publication Critical patent/MA26836A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA26611A 1999-10-21 2002-04-19 Heterocycles azotes bicycliques alkylamino substitues en tant qu'inhibiteurs de kinase de proteine p38. MA26836A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16080499P 1999-10-21 1999-10-21
US21371800P 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
MA26836A1 true MA26836A1 (fr) 2004-12-20

Family

ID=26857242

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26611A MA26836A1 (fr) 1999-10-21 2002-04-19 Heterocycles azotes bicycliques alkylamino substitues en tant qu'inhibiteurs de kinase de proteine p38.

Country Status (24)

Country Link
US (1) US6642241B1 (fr)
EP (1) EP1226144B1 (fr)
KR (1) KR100537241B1 (fr)
CN (1) CN1156477C (fr)
AR (1) AR026187A1 (fr)
AT (1) ATE349447T1 (fr)
AU (1) AU776695B2 (fr)
BR (1) BR0014973A (fr)
CA (1) CA2388140C (fr)
CO (1) CO5251408A1 (fr)
CZ (1) CZ20021743A3 (fr)
DE (1) DE60032623T2 (fr)
ES (1) ES2277858T3 (fr)
HR (1) HRP20020327A2 (fr)
HU (1) HUP0203477A3 (fr)
IL (1) IL149230A0 (fr)
MA (1) MA26836A1 (fr)
MX (1) MXPA02003841A (fr)
NO (1) NO20021783L (fr)
PE (1) PE20010760A1 (fr)
PL (1) PL357494A1 (fr)
TR (1) TR200201058T2 (fr)
WO (1) WO2001029041A1 (fr)
YU (1) YU29202A (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003429T2 (tr) 1998-05-26 2001-07-23 Warner-Lambert Company Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.
US20040044012A1 (en) * 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
KR20040103972A (ko) * 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
AU2003251661A1 (en) * 2002-08-06 2004-02-25 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
KR100793688B1 (ko) * 2002-08-06 2008-01-10 에프. 호프만-라 로슈 아게 Ｐ-38 미토겐 활성 단백질 키나제 억제제로서6-알콕시-피리도-피리미딘
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7112676B2 (en) * 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
WO2004089955A1 (fr) * 2003-04-10 2004-10-21 F.Hoffmann-La Roche Ag Composes pyrimido
JP4659736B2 (ja) * 2004-04-27 2011-03-30 武田薬品工業株式会社 スクリーニング方法
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
AU2005279337A1 (en) 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
JP2008510690A (ja) 2004-08-31 2008-04-10 エフ．ホフマン−ラ ロシュ アーゲー ３−フェニル−ジヒドロピリミド［４，５−ｄ］ピリミジノンのアミド誘導体、これらの製造、及び医薬品としての使用
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
ES2329419T3 (es) 2006-01-31 2009-11-25 F. Hoffmann-La Roche Ag 7h-pirido(3,4-d)pirimidin-8-onas, su preparacion y uso como inhibidores de proteinas cinasas.
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
EP2108641A1 (fr) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Nouveaux dérivés substitués de spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one et leur utilisation comme ihibiteurs de p38 mitogen-activated kinase
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP3943087A1 (fr) 2013-03-15 2022-01-26 Celgene CAR LLC Composés hétéroaryle et utilisations associées
CN105307657B (zh) 2013-03-15 2020-07-10 西建卡尔有限责任公司 杂芳基化合物和其用途
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CA3157361A1 (fr) 2019-10-14 2021-04-22 Incyte Corporation Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (fr) 2021-04-12 2022-10-20 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques utiles en tant qu'inhibiteurs de fgfr

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
BR9812944A (pt) * 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
TR200003429T2 (tr) * 1998-05-26 2001-07-23 Warner-Lambert Company Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.
HK1041483B (zh) * 1998-10-23 2004-12-24 霍夫曼-拉罗奇有限公司 雙環氮雜環

Also Published As

Publication number Publication date
NO20021783D0 (no) 2002-04-16
AU1137501A (en) 2001-04-30
EP1226144A1 (fr) 2002-07-31
ATE349447T1 (de) 2007-01-15
HRP20020327A2 (en) 2004-02-29
EP1226144B1 (fr) 2006-12-27
CA2388140A1 (fr) 2001-04-26
JP4028236B2 (ja) 2007-12-26
KR100537241B1 (ko) 2005-12-19
PE20010760A1 (es) 2001-07-21
WO2001029041A1 (fr) 2001-04-26
PL357494A1 (en) 2004-07-26
ES2277858T3 (es) 2007-08-01
IL149230A0 (en) 2002-11-10
AU776695B2 (en) 2004-09-16
HK1051040A1 (en) 2003-07-18
CO5251408A1 (es) 2003-02-28
CA2388140C (fr) 2008-09-02
DE60032623T2 (de) 2007-10-11
YU29202A (sh) 2004-12-31
CN1382142A (zh) 2002-11-27
DE60032623D1 (de) 2007-02-08
CN1156477C (zh) 2004-07-07
JP2003512377A (ja) 2003-04-02
KR20020039375A (ko) 2002-05-25
TR200201058T2 (tr) 2002-07-22
HUP0203477A3 (en) 2004-12-28
US6642241B1 (en) 2003-11-04
NO20021783L (no) 2002-04-16
MXPA02003841A (es) 2002-09-30
CZ20021743A3 (cs) 2002-08-14
BR0014973A (pt) 2002-07-16
HUP0203477A2 (hu) 2003-01-28
AR026187A1 (es) 2003-01-29

Similar Documents

Publication Publication Date Title
MA26836A1 (fr) Heterocycles azotes bicycliques alkylamino substitues en tant qu'inhibiteurs de kinase de proteine p38.
MA26837A1 (fr) Heterocycles azotes bicycliques heteroalky-lamino substitues en tant qu'inhibiteurs de kinase de proteine p38.
FR14C0055I2 (fr) Cyanoquinolines 3 substituees en tant qu'inhibiteurs de kinases de la proteine tyrosine
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
MA26782A1 (fr) Pyrazolobenzodiazepines en tant qu'inhibiteurs de cdk2.
MA26831A1 (fr) Derives de benzodiazepine."
MA25493A1 (fr) Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux.
MA26819A1 (fr) Pteridinones servant d' inhibiteurs de kinases.
ZA200306341B (en) Imidazo (1,2-a)-pyridine derivatives as mGluR5 antagonists.
ZA200202775B (en) Quinazoline derivatives as VEGF inhibitors.
NL300203I1 (nl) Antiviraal werkzame heterocyclische azahexaan-derivaten.
MA26932A1 (fr) Derives d'imidazole.
DE69918528D1 (de) Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
MA26824A1 (fr) 5-(2-substitué-5-hétérocyclylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidine-7-ones servant d'inhibiteurs de phosphodiestérase.
NO20004809D0 (no) Trisubstituerte 1,3,5-triazinderivater for behandling av HIV- infeksjoner
MX9204425A (es) Derivados de quinazolina como inhibidores de la acetilcolinesterasa.
IS5715A (is) Aðferð til smíði á 4-karboxýamínó-2-setnu-1,2,3,4-tetrahýdrókínólíni
BR0014775B1 (pt) misturas antimicrobianas de 1,3-bis (hidroximetil) -5,5-dimetilidantoina e 1,2-benzisotiazolin-3-ona.
IT1317751B1 (it) Poliolefine di metalloceni stabilizzate.
FI953104L (fi) Diaryyli-5,6-kondensoidut heterosykliset hapot leukotrieeniantagonisteina
ATE240326T1 (de) Pyrrolo-(3,2-b)pyridine und ihre verwendung als 5-ht1f agonisten
IT1313592B1 (it) Derivati di 1h-pirido 3,4-b indol-1-one.
FR11C0047I2 (fr) Acides 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-(4.3.0)-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinocarboxyliques eventuellement substitues et leurs derives
NO20014059L (no) Krystallmodifikasjon D av 8-cyano-1-cyklopropyl-7-(1S,6S-2,8- diazabicyklo-/4.3.0/-nonan-8-yl)-6-fluor-1,4-dihydro-4-okso-3-kinolinkarboksylsyre
NL194530B (nl) Takhouder, alsmede plano voor het vormen hiervan.